Viking Therapeutics Announces Promising Top-Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)

Tuesday, June 6, 2017 1 min read

Key Takeaway: Viking Therapeutics Announces Promising Top-Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)

Full Press Release Details

Viking Therapeutics Announces Promising Top-Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH).